<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01501786</url>
  </required_header>
  <id_info>
    <org_study_id>ketamine in sedation</org_study_id>
    <nct_id>NCT01501786</nct_id>
  </id_info>
  <brief_title>Does Ketamine Attenuate Depression of Respiratory and Cardiac Functions</brief_title>
  <official_title>The Effect of Small-dose Ketamine on Depression of Respiratory and Cardiac Functions Caused by Propofol in Pediatric Cardiac Catheterization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ibaraki Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ibaraki Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Normal cardiac and respiratory functions should be maintained during pediatric cardiac
      catheterization. Propofol has become a popular choice for sedation in children, however, it
      depresses cardiac and respiratory functions. Some investigators reported that ketamine
      attenuates its depressant effect, but it remains unclear whether ketamine reduces cardiac and
      respiratory depression caused by propofol in pediatric cardiac catheterization.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>difference of end tidal partial pressure of carbon dioxide between the groups</measure>
    <time_frame>30 and 60 min after anesthetic induction</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>difference of partial pressure of arterial carbon dioxide between the groups</measure>
    <time_frame>60 min after anesthetic induction on average</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>heart rate change from baseline value</measure>
    <time_frame>30 and 60 min after anesthetic induction</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>non-invasive blood pressure change from baseline value</measure>
    <time_frame>30 and 60 min after anesthetic induction</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>movement at topical anesthetic injection</measure>
    <time_frame>20 min after anesthetic induction on average</time_frame>
    <description>none (no movement or slight movement unnecessary to restrain)
mild (movement necessary to restrain, limited to lower extremities)
moderate (strong movement of lower extremities and movement of upper extremities unvecessary to restrain)
severe (movement necessary to restrain upper extremities and body trunk in addition to lower extremities, or some vacalization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the number of times that secreted saliva is aspirated by an attending anesthesiologist</measure>
    <time_frame>From anesthetic induction to termination of anethetics administration, which is not over 2 hours from anesthetic induction</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Congenital Heart Disease</condition>
  <condition>Sedated for Cardiac Catheterization</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>propofol and saline are administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ket10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ketamine is co-administered with propofol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ket20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ketamine is co-administered with porpofol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>control</intervention_name>
    <description>propofol 8mg/kg/h saline 0.24 ml/kg/h</description>
    <arm_group_label>control</arm_group_label>
    <other_name>saline with propofol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ket10</intervention_name>
    <description>propofol 6.4 mg/kg/h ketamine 10 microg/kg/min</description>
    <arm_group_label>Ket10</arm_group_label>
    <other_name>ketamine 10 γ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ket20</intervention_name>
    <description>propofol 4.8 mg/kg/h ketamine 20 microg/kg/min</description>
    <arm_group_label>Ket20</arm_group_label>
    <other_name>ketamine 20 γ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  7kg-25kg (6mo-10yrs) children who undergo cardiac catheterization

        Exclusion Criteria:

          -  patients who have neurological disease,

          -  endocrinological disease,

          -  airway anomaly, who require positive pressure ventilation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kazuhiko Okuyama, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ibaraki Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuki Takeda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ibaraki Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ibaraki Children's Hospital</name>
      <address>
        <city>Mito</city>
        <state>Ibaraki</state>
        <zip>311-4145</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2011</study_first_submitted>
  <study_first_submitted_qc>December 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2011</study_first_posted>
  <last_update_submitted>July 28, 2013</last_update_submitted>
  <last_update_submitted_qc>July 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ibaraki Children's Hospital</investigator_affiliation>
    <investigator_full_name>Kazuhiko Okuyama, MD</investigator_full_name>
    <investigator_title>Head of Anesthesiology department</investigator_title>
  </responsible_party>
  <keyword>children</keyword>
  <keyword>sedation</keyword>
  <keyword>propofol</keyword>
  <keyword>ketamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

